Reuters logo
UPDATE 1-Depomed posts surprise Q3 profit
November 1, 2010 / 9:16 PM / 7 years ago

UPDATE 1-Depomed posts surprise Q3 profit

* Q3 EPS $0.04 vs est loss/shr $0.02

* Q3 revenue $20.1 mln in line with est

Nov 1 (Reuters) - Depomed Inc (DEPO.O) posted a surprise quarterly profit, helped by an upfront license fee from Merck & Co (MRK.N) and milestone revenue from two products.

For the third quarter, the specialty pharmaceutical company reported net income of $1.9 million, or 4 cents a share, compared with $1.4 million, or 3 cents a share, a year earlier. Revenue fell 13 percent to $20.1 million.

Analysts on average expected a loss of 2 cents a share, on revenue of $20.1 million, according to Thomson Reuters I/B/E/S.

The company recorded $6 million from milestones and received an upfront license fee of $10 million from Merck.

Operating expenses fell 22 percent to $15.7 million.

Depomed shares, which have risen 49 percent since the company posted its second-quarter results in August, closed at $4.94 on Monday on Nasdaq. (Reporting by Shravya Jain in Bangalore; Editing by Vinu Pilakkott)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below